WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Danya J. Martell Smart
Patent Agent
Patents and Innovations
Boston
dsmart@wsgr.com

D617-598-7856

Download vCard
Open PDF

Dr. Danya J. Martell Smart is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where her work focuses on patents and innovations primarily in the life sciences, biotechnology, and related industries. Danya has experience in molecular biology, genomics, gene editing, next-generation sequencing, bioinformatics, protein engineering, protein biochemistry, and fluorescence microscopy.

Prior to joining the firm, Danya was a postdoctoral fellow in the Department of Genetics at Harvard Medical School, and in the Department of Hematology at Boston’s Children’s Hospital in the labs of Dr. L. Stirling Churchman and Dr. Vijay G. Sankaran, respectively. During her postdoctoral studies, she applied CRISPR/cas9 genome editing to primary human hematopoietic stem cells to study blood disease, utilized genome-wide association studies to probe pathogenic mutations in essential transcription factors, analyzed nascent transcript behavior during cellular differentiation, quantified the effects of drug treatments on stem cells, and helped improve a high-throughput sequencing methodology for investigating transcription elongation. Danya earned her Ph.D. at Cornell University in Chemistry and Chemical Biology in the lab of Dr. Peng Chen where she quantified transcription factor and DNA conformational dynamics using single-molecule fluorescent microscopy.

Experience

Dr. Danya J. Martell Smart is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where her work focuses on patents and innovations primarily in the life sciences, biotechnology, and related industries. Danya has experience in molecular biology, genomics, gene editing, next-generation sequencing, bioinformatics, protein engineering, protein biochemistry, and fluorescence microscopy.

Prior to joining the firm, Danya was a postdoctoral fellow in the Department of Genetics at Harvard Medical School, and in the Department of Hematology at Boston’s Children’s Hospital in the labs of Dr. L. Stirling Churchman and Dr. Vijay G. Sankaran, respectively. During her postdoctoral studies, she applied CRISPR/cas9 genome editing to primary human hematopoietic stem cells to study blood disease, utilized genome-wide association studies to probe pathogenic mutations in essential transcription factors, analyzed nascent transcript behavior during cellular differentiation, quantified the effects of drug treatments on stem cells, and helped improve a high-throughput sequencing methodology for investigating transcription elongation. Danya earned her Ph.D. at Cornell University in Chemistry and Chemical Biology in the lab of Dr. Peng Chen where she quantified transcription factor and DNA conformational dynamics using single-molecule fluorescent microscopy.

Education
  • Postdoctoral Fellow, Department of Genetics at Harvard University and Department of Hematology at Boston Children’s Hospital, 2023

    Recipient, Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship

  • Ph.D., Chemistry and Chemical Biology, Cornell University, 2016

    Recipient, Bauer Scholarship Award; Recipient, Howard Neal Wachter Memorial Prize

  • M.S., Chemistry and Chemical Biology, Cornell University, 2012

    Recipient, Chemistry-Biology Interface Training Grant, National Institute of Health

  • B.S., Biochemistry, California State University, Northridge, 2010

    Cum Laude; Recipient, Presidential and University Scholar; Recipient, Hypercube Scholar Award; Recipient, Hugo and Irma Oppenheimer Award

Associations and Memberships
  • Event organizer, Association for Women in Science
  • Mentor, Harvard Graduate Women in Science and Engineering
  • Mentor, Encouraging Young Engineers and Scientists
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Postdoctoral Fellow, Department of Genetics at Harvard University and Department of Hematology at Boston Children’s Hospital, 2023

    Recipient, Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship

  • Ph.D., Chemistry and Chemical Biology, Cornell University, 2016

    Recipient, Bauer Scholarship Award; Recipient, Howard Neal Wachter Memorial Prize

  • M.S., Chemistry and Chemical Biology, Cornell University, 2012

    Recipient, Chemistry-Biology Interface Training Grant, National Institute of Health

  • B.S., Biochemistry, California State University, Northridge, 2010

    Cum Laude; Recipient, Presidential and University Scholar; Recipient, Hypercube Scholar Award; Recipient, Hugo and Irma Oppenheimer Award

Associations and Memberships
  • Event organizer, Association for Women in Science
  • Mentor, Harvard Graduate Women in Science and Engineering
  • Mentor, Encouraging Young Engineers and Scientists
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author with D.R. Higgs, V.G. Sankaran, L.S. Churchman, et al., “RNA Polymerase II pausing temporally coordinates cell cycle progression and erythroid differentiation,” Developmental Cell, 2023
  • Co-author with L.S. Churchman, et al., “Profiling metazoan transcription genome-wide with nucleotide resolution using native elongating transcript sequencing,” Protocols.io, 2021
  • Co-author with P. Chen, et al., “Metalloregulator CueR biases RNA polymerase’s kinetic sampling of dead-end or open complex to repress or activate transcription,” 112 Proceedings of the National Academy of Sciences USA 13467-13472, 2015
  • Co-author with P. Chen, et al., “Concentration- and chromosome-organization-dependent regulator unbinding from DNA for transcription regulation in living cells,” 6 Nature Communications 7445, 2015
  • Co-author with P. Chen, et al., “Single-Molecule Dynamics and Mechanisms of Metalloregulators and Metallochaperones,” 52 Biochemistry 7170-7183, 2013
  • Co-author with J.D. Helmann, P. Chen, et al., “Direct substitution and assisted dissociation pathways for turning off transcription by a MerR-family metalloregulator,” 109 Proceedings of the National Academy of Sciences USA 15121-15126, 2012

Select Speaking Engagements

  • Speaker, “RNA Polymerase II pausing coordinates stage-selective cell cycle progression and erythroid differentiation,” Globin Switching Conference in Crete, Greece, May 06, 2022
  • Speaker, “Regulation of transcription elongation during red blood cell differentiation,” Harvard Medical School Department of Genetics in Boston, Massachusetts, April 26, 2019
  • Speaker, “Insight into the Mechanisms of Transcription by a MerR-family Metalloregulator through Single-Molecule Analysis,” Bauer Scholarship Award presentation at California State University in Northridge, California, March 25, 2015
  • Speaker, “Single-Molecule Analysis Suggests Novel Pathways for Turning off Transcription by a MerR-family Metalloregulator,” Cornell University Graduate Student Award Symposium in Ithaca, New York, April 23, 2013
Insights

Select Publications

  • Co-author with D.R. Higgs, V.G. Sankaran, L.S. Churchman, et al., “RNA Polymerase II pausing temporally coordinates cell cycle progression and erythroid differentiation,” Developmental Cell, 2023
  • Co-author with L.S. Churchman, et al., “Profiling metazoan transcription genome-wide with nucleotide resolution using native elongating transcript sequencing,” Protocols.io, 2021
  • Co-author with P. Chen, et al., “Metalloregulator CueR biases RNA polymerase’s kinetic sampling of dead-end or open complex to repress or activate transcription,” 112 Proceedings of the National Academy of Sciences USA 13467-13472, 2015
  • Co-author with P. Chen, et al., “Concentration- and chromosome-organization-dependent regulator unbinding from DNA for transcription regulation in living cells,” 6 Nature Communications 7445, 2015
  • Co-author with P. Chen, et al., “Single-Molecule Dynamics and Mechanisms of Metalloregulators and Metallochaperones,” 52 Biochemistry 7170-7183, 2013
  • Co-author with J.D. Helmann, P. Chen, et al., “Direct substitution and assisted dissociation pathways for turning off transcription by a MerR-family metalloregulator,” 109 Proceedings of the National Academy of Sciences USA 15121-15126, 2012

Select Speaking Engagements

  • Speaker, “RNA Polymerase II pausing coordinates stage-selective cell cycle progression and erythroid differentiation,” Globin Switching Conference in Crete, Greece, May 06, 2022
  • Speaker, “Regulation of transcription elongation during red blood cell differentiation,” Harvard Medical School Department of Genetics in Boston, Massachusetts, April 26, 2019
  • Speaker, “Insight into the Mechanisms of Transcription by a MerR-family Metalloregulator through Single-Molecule Analysis,” Bauer Scholarship Award presentation at California State University in Northridge, California, March 25, 2015
  • Speaker, “Single-Molecule Analysis Suggests Novel Pathways for Turning off Transcription by a MerR-family Metalloregulator,” Cornell University Graduate Student Award Symposium in Ithaca, New York, April 23, 2013

Biological Sciences and Biotechnology

  • Biophysics
  • Cell biology
  • Cell therapy
  • Cellular biology
  • Genetics
  • Molecular biology
  • Molecular genetics
  • Stem cell biology

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • CRISPR
  • Gene editing
  • Gene therapy

Diagnostics and Medical Devices

  • Bioinformatic

Chemistry and Material Science

  • Protein engineering

Genomics and Data Analysis

  • Next-generation sequencing
  • Sequencing
  • Single-cell sequencing

Miscellaneous

  • Fluorescence microscopy
Technical Fluency

Biological Sciences and Biotechnology

  • Biophysics
  • Cell biology
  • Cell therapy
  • Cellular biology
  • Genetics
  • Molecular biology
  • Molecular genetics
  • Stem cell biology

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • CRISPR
  • Gene editing
  • Gene therapy

Diagnostics and Medical Devices

  • Bioinformatic

Chemistry and Material Science

  • Protein engineering

Genomics and Data Analysis

  • Next-generation sequencing
  • Sequencing
  • Single-cell sequencing

Miscellaneous

  • Fluorescence microscopy
Focus Areas
  • Biotech
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Metagenomi on IP Matters Related to $93 Million IPO
On February 13, 2024, Metagenomi, Inc., a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The shares began trading on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol “MGX.” The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.
Learn More
Recent Events
Affiliated Programs
2025 Entrepreneur and Investor Life Sciences Summit (E&I Summit), presented by BioUtah
Wilson Sonsini is looking forward to the 2025 Entrepreneur & Investor Life Sciences Summit (E&I Summit), presented by BioUtah and the University of Utah Technology Licensing Office. Now in its 12th year, the E&I Summit convenes Utah’s life sciences leaders, entrepreneurs, and the investor community.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.